165 results about "Immune correlates" patented technology

The invention relates to the technical field of microorganisms, and provides Witzia ciliaris KY009 (preservation number is CGMCC (China General Microbiological Culture Collection Center) NO. 33480) and Clostridium butyricum KY002 (preservation number is CGMCC NO. 33478), and the two strains are separated from an excrement sample. Experiments prove that the two strains can obviously improve the sperm quality and quantity, regulate the sex hormone level, improve the intestinal inflammation symptom and regulate the expression of related inflammatory factors. The invention also provides a composition containing the two strains, wherein the composition comprises a food composition, a pharmaceutical composition, a health-care product composition, a functional microbial agent and the like. The compositions are useful for improving reproductive health, modulating sex hormone levels, treating intestinal inflammation and promoting mucosal repair, and alleviating metabolic and immune related diseases. The strain and the composition provided by the invention have wide application prospects in the fields of medicines, foods and health-care products.

The invention discloses a method for generating a personalized vaccination scheme of a rabies vaccine in combination with an electronic medical record, and relates to the technical field of intelligent vaccination management, and the method comprises the following steps: extracting all structured feature information and unstructured feature information related to immune function evaluation in the electronic medical record of a patient, and constructing a feature data original mapping table; according to the method, by constructing the feature mapping table, the conflict relation matrix and the propagation path diagram, the logic conflict of the immune related information in the electronic medical record is accurately identified, the conflict intensity is quantified, the risk index is generated, and then the inoculation strategy path of the main feature and the alternative feature is dynamically adjusted. According to the method, the adaptability and fault-tolerant ability of the system to multi-source heterogeneous medical data are improved, decision deviation caused by feature conflicts is effectively avoided, the scientificity and safety of a personalized vaccination scheme of the rabies vaccine are enhanced, and the method has remarkable clinical and public health values.

The invention relates to the technical field of biomedicine, in particular to a method for constructing a plasma ctDNA organ distribution characteristic spectrum of advanced colorectal cancer. The method comprises the following steps: collecting a peripheral blood sample at multiple time points, separating plasma by adopting a double-centrifugal method, and extracting circulating tumor DNA (Deoxyribose Nucleic Acid); carrying out whole exome sequencing based on ctDNA to obtain genome variation information and calculating variation allele frequency, and synchronously detecting the expression quantity of immune-related proteins by adopting an Olink proteomics technology; integrating the genome data, the protein expression data and the clinical pathological features, and constructing a multi-dimensional feature data matrix; and taking the organ metastasis condition confirmed by iconography as a supervision label, training a model by applying a machine learning algorithm, screening key prediction factors, constructing a quantitative prediction model, and finally generating a visual organ metastasis tendency prediction map. According to the method, early and accurate prediction of the advanced colorectal cancer organ metastasis tendency is realized through multi-omics data collaborative analysis and machine learning modeling.

Provided are a novel modified side chain, and a preparation method therefor and a use thereof. In particular, provided are a modified side chain as represented by general formula (I), and a preparation method therefor, a pharmaceutical composition containing same, and a use thereof in the preparation of drugs for treating cancer, infections, neuropsychiatric diseases, cardiovascular diseases, endocrine diseases, and immune-related diseases.

The subject matter described here relates to anti-PD-1 x anti-IL-25 bispecific antibodies. In certain embodiments the bispecific antibody is used for the treatment or prevention of cancer. In certain embodiments the bispecific antibody is used for the treatment or prevention of breast cancer. In some embodiments, the bispecific antibody limits immune related adverse events.

Methods are disclosed related to identifying small molecule metabolites that serve as biomarkers of immune related adverse events (irAEs). In embodiments, treatments are disclosed that reduce the likelihood or prevent irAEs.

The invention relates to the technical field of bioengineering, in particular to a preparation method of a probiotic and exosome preparation applied to immunoregulation. The probiotics and the umbilical cord stem cell exosome are combined for use, the immune regulation effect is enhanced from multiple targets and multiple ways, the immune function of the body is improved, the exosome carries a specific molecular marker and acts on immune cells in a targeted mode, precise immune regulation is achieved, and the preparation is in an oral form and convenient to use; the exosome is extracted from umbilical cord stem cells, has no pathogenicity and immunogenicity, and is low in adverse reaction risk after being used for a long time, and the prepared combined preparation can be used for treating and preventing various immune-related diseases, and also can be used for daily conditioning of people with low immunity and improving the body resistance; meanwhile, the combined preparation adopts micro-capsule embedding, so that the probiotics can be effectively protected from gastric acid and bile erosion, the survival rate and colonization efficiency of the probiotics in intestinal tracts are improved, the immunoregulation effect is further enhanced, and the combined preparation is convenient to store and transport and has a good application prospect.

The present invention relates to a method for identifying immune-related microorganisms in colorectal cancer based on multi-omics features, and belongs to the field of biomedicine technology. The method includes analyzing the diversity and composition of intestinal flora in colorectal cancer patients and healthy controls; identifying intestinal microorganisms significantly associated with patients through the LASSO algorithm; selecting characteristic intestinal microorganisms of colorectal cancer by the SVM-RFE method; obtaining overlapping genes between the two algorithms, and incorporating the overlapping genes into ROC and DCA analysis verification; the method includes screening key microorganisms for immune regulation, predictive analysis of immune-related intestinal microbial functions, analysis of immune-related microorganisms and immune microenvironment, and prediction of the mechanism of action of immune-related intestinal microorganisms; the method of the present invention can screen out key microorganisms with immune regulatory effects in colorectal cancer, laying the foundation for studying the mechanism of action of intestinal flora and formulating personalized precision medication plans.

The invention belongs to the technical field of biological medicine, and relates to pharmaceutical application of an oxidative phosphorylation inhibitor, in particular to application of the oxidative phosphorylation inhibitor in preparation of an immunomodulatory drug, and the immunomodulatory drug has the advantages that the function damage of newborn myeloid-derived suppressor cells caused by antagonism BCG (bacillus calmette guerin) vaccination is inhibited, and the immunomodulatory effect is improved. The compound is used for preventing or treating neonatal immune-related diseases caused by bacillus calmette guerin vaccine inoculation. The invention finds that the BCG can cause damage to the immunosuppression function of the MDSC of the suckling mouse through up-regulation oxidative phosphorylation, and the negative effect caused by inoculation of the BCG can be reversed by using the OXPHOS inhibitor, so that the immunosuppression function of the MDSC of the suckling mouse is successfully recovered in an in-vivo and in-vitro model, and the immune-related adverse reaction caused by inoculation of the BCG is expected to be improved.

Compounds that inhibit PI3Kγ, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by PI3Kγ.

The invention relates to the technical field of medical chemistry and tumor treatment, in particular to application of a novel NOX4 inhibitor ZZU026 and derivatives thereof in tumor resistance and immune response change. The preparation method of the ZZU026 comprises the following steps: replacing N, N-dimethylamino on a benzene ring of GKT137831 with morpholinyl; methoxyl is introduced into the core skeleton. The ZZU026 has a remarkable inhibiting effect on NOX4, has the functions of inhibiting tumor growth, new vascularization and immune-related diseases, regulating and controlling polarization of macrophages and the like, and can inhibit phenotype transformation of macrophages from M1 to M2 and finally inhibit proliferation and immune escape of lung cancer cells; the ZZU026 and the derivatives thereof can be prepared into drugs, health care products, tablets, particles, capsules, oral liquid or injection, and can be used for treating lung cancer and other tumors.

The invention relates to the technical field of chemical toxicology, in particular to an evaluation method for comprehensively analyzing the immune induction effect of a plasticizer by using caenorhabditis elegans, according to the evaluation method, a mother worm breeding mode is changed to replace a lysis solution to synchronize nematodes, experimental interference is reduced, the result accuracy is improved, monitoring indexes are newly increased, intestinal injuries and in-vivo bacterial indexes are increased, and the evaluation method is suitable for comprehensive analysis of the immune induction effect of the plasticizer. The evaluation is more accurate and reliable by combining oxidative stress indexes and performing two-dimensional comprehensive evaluation from an intestinal immune defense line and oxidative stress, and by drawing a multi-index monitoring shape graph, adopting a comprehensive biomarker response index analysis method and associating immune-related representative indexes, the evaluation accuracy is improved. According to the method, the change of each index and the immunity intensity on the caenorhabditis elegans under different exposure conditions are intuitively presented, the immune defense effect of the caenorhabditis elegans under the stress of the plasticizer can be quickly and effectively evaluated without transcriptome and metabonomics, and efficient evaluation is realized.

The present disclosure generally relates to compositions and methods for predicting or diagnosing immune-related adverse events (irAE) before, during, or after immune checkpoint inhibitor (ICI) treatment in a subject with cancer. The method includes assessment of immune cell types, cytokines, autoantibodies or any combination thereof.

This invention relates to the field of molecular biology, specifically to the application of miR-193a-5p antagonists in the preparation of drugs for treating immune-associated pneumonia, the sequence of which is shown in SEQ ID NO: 1. This invention experimentally demonstrates for the first time that miR-193a-5p expression is significantly upregulated in an immune-associated pneumonia model, and that the use of its specific antagonist can effectively alleviate pneumonia symptoms; therefore, miR-193a-5p antagonists can be used as active ingredients in the preparation of drugs for treating immune-associated pneumonia caused by immune checkpoint inhibitors.

The invention discloses a PD-L1 monoclonal antibody delivery system as well as a preparation method and application thereof, and belongs to the technical field of medicines. The preparation method comprises the following steps: coupling amino groups of BPA-PEG9 and a PD-L1 monoclonal antibody through NHS (N-hydroxysuccinimide) esterification to form BPA6-aPDL1; the preparation method comprises the following steps: grafting a glucose derivative maltomimetic acid MA of o-benzene dihydroxyl to a lipid-like amphiphilic molecule PEG (Polyethylene Glycol) (1.5 k-DSPE) through an amido bond to form MA4-PEG (1.5 k-DSPE), namely MA4-PD; then, the BPA6-aPDL1 reacts with the MA4-PD through a boric acid ester bond, and finally, the delivery system MB-aPDL1 is formed. The delivery system not only can successfully deliver the PD-L1 to a tumor site across a blood brain barrier, but also can accurately release the PD-L1 monoclonal antibody, so that the PD-L1 monoclonal antibody is only enriched in a tumor region, the residence time of the antibody is prolonged, the tumor anchoring capability of the antibody is improved, and the occurrence of immune-related adverse events is remarkably reduced.

The invention relates to a nutritional composition for improving an intestinal immune function and application thereof, and belongs to the technical field of microorganisms. The nutritional composition of the present invention comprises a bifidobacterium bifidum (Bifidobacterium bifidum), and a breast milk oligosaccharide. The breast milk oligosaccharide in the nutritional composition can provide a growth substrate for the bifidobacteria and promote colonization of the bifidobacteria in intestinal tracts. The bifidobacterium bifidum produces beneficial metabolites by metabolizing oligosaccharide in breast milk, and plays an immune regulation role. According to the nutritional composition, the intestinal immune function is remarkably improved, the intestinal flora structure is optimized, and the risk of immune-related diseases is reduced.

The application discloses a use of ubiquitination as a marker of systemic juvenile idiopathic arthritis, and relates to the technical field of biomedicine. The marker provided by the application is a gene combination of at least two genes in ubiquitination which participates in the occurrence of sJIA inflammation by mediating NLRs pathway; the ubiquitination includes HP, S100A9, S100A12, S100A8, IL6, CFH and UBE2D1; and the gene combination at least includes a combination of any one of HP and IL6 and UBE2D1. The application constructs a joint detection scheme of UBE2D1 and inflammatory factors, chemotactic factors or immune-related molecules, and can make up for the problems of insufficient stability or limited specificity of a single index to some extent, thereby improving the auxiliary diagnosis efficiency on sJIA. Meanwhile, the detection object involved in the application is clear, the detection mode is feasible, the detection can be carried out based on a blood sample, and the application has the advantages of relatively simple operation, strong clinical implementability, convenience for development into a detection kit, a detection chip or a matching detection reagent.

Relates to the field of biological medicine, in particular to an antibody specifically binding to IL35 and IL27 and application thereof, and the antibody not only can inhibit binding of IL35 and a receptor thereof, but also can inhibit binding of IL27 and a receptor thereof. Meanwhile, the invention also relates to a nucleic acid sequence for coding the antibody, a carrier and a cell containing the nucleic acid sequence, a pharmaceutical composition containing the antibody, and application of the antibody or the composition containing the antibody to preparation of drugs for treating immune-related diseases and cancers.

The invention discloses a biphenyl compound as shown in a formula (I), and a preparation method and application thereof. The invention also relates to a pharmaceutical composition containing the compound as an active ingredient. The compound is a novel small molecule immunomodulator having an excellent oral absorbable characteristic, and can be used for treating and / or preventing various diseases related to immunity.

A corneal tissue exosome collected after rapid culture of a corneoscleral tissue directly following corneal transplantation is disclosed. The overall manufacturing process is simple, eliminating the procedures of thawing, isolation, and cell culture in conventional cell culture processes, and possesses high production yield and homogeneity, while reducing the generation of biomedical waste. The corneal tissue exosome obtained from the corneoscleral tissue exhibits specific protein expression and possesses potential for treating wound repair, ocular diseases, cancer, and immune-related diseases.

Compounds that modulate the conversion of AMP to adenosine by 5′-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and / or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5′-nucleotidase, ecto is also provided.

This invention relates to the field of biomedicine, specifically providing a mutant thymosin α1 polypeptide and its applications. The mutant differs from natural thymosin α1 by substituting at least one amino acid at positions 15, 21, and 27, with preferred mutations including D15M, E21W, and E27R. Amino acid substitutions at these sites significantly improve the structural stability and in vivo pharmacokinetic properties of thymosin α1. Experimental results show that, while maintaining the main secondary structural features and overall thermal stability without significant degradation, the mutant improves serum stability and in vivo pharmacokinetic properties, exhibiting superior in vivo half-life and antitumor activity. This invention also provides nucleic acid molecules encoding the mutant, expression vectors, host cells, and pharmaceutical compositions containing the mutant, which can be used for the treatment of tumors, viral infections, and immune-related diseases.

Formula (I) (in the formula, rings A, W, X, Y, L 1 , R 1 , R 3 and R 4 Compounds of Formula (I), and pharmaceutically acceptable salts thereof, are useful for treating or preventing cancer or immune-related diseases or conditions. Also described are pharmaceutical compositions of the compounds of Formula (I), and methods of using such compounds and compositions.

The application provides an animal immune evaluation method based on a Lutzomyia longipalpis infection model, and comprises the following steps: S1, experimental animal preparation and screening; S2, Lutzomyia longipalpis preparation and quality verification; S3, Lutzomyia longipalpis infection of experimental animals; S4, immune related index detection; S5, animal immune function evaluation; and S6, repeatability verification and data summarization. The application realizes systematic and objective evaluation of the effect of immune candidate drugs.

The invention belongs to the technical field of bioengineering, and particularly relates to an engineered IL-6 / IL-12 family subunit combination and application thereof. A beta subunit and an alpha subunit are connected through a flexible polypeptide connecting peptide in a covalent mode to form a stable compound, and the stable compound comprises a subunit combination (p35 / sIL-6R alpha) composed of p35 and soluble IL-6R alpha and a subunit combination (IL-6 / p40) composed of IL-6 and p40. The engineered IL-6 / IL-12 family subunit combination disclosed by the invention has immunomodulatory activity, can be used for regulating immune response, and can be used as a research tool or used for preparing a pharmaceutical composition for treating immune-related diseases.

The invention relates to an InDel molecular marker related to immune traits of Landaise geese and application of the InDel molecular marker, and belongs to the technical field of molecular markers. The InDel molecular marker provided by the invention is located in a full-length sequence of a CNTFR gene as shown in SEQ ID No.1, and insertion of a single base T exists at the 165833rd site. The InDel molecular marker disclosed by the invention can be used for quickly and accurately distinguishing the high / low ratio of heterophilic granulocytes / lymphocytes of the Landaise geese, has the advantages of simplicity and convenience in operation and reliable result, and provides an effective molecular basis for directional breeding of immune-related traits of the Landaise geese.

The present disclosure provides methods of predicting / diagnosing immunotherapeutic toxicity in a subject using levels of at least one biomarker protein in a biological sample from the subject, wherein the at least one biomarker protein comprises C4orf47, CXCL1, LMNTD2, ERVV-1, PSRC1, SPRED2, KIF22, MRRF, DAAM1, ABO, MAP9, or any combination thereof. Also provided herein are methods of determining therapeutic regimens for patients based on the biomarker levels.

The invention discloses immune factor detection test paper and a preparation method thereof, and relates to the technical field of biomedicine. The test paper structurally comprises a bottom plate, a sample pad, a binding pad, a nitrocellulose membrane and absorbent paper, and multi-index joint detection is realized by coating a specific detection antibody on the binding pad and coating a specific capture substance on a detection line. The test paper has the advantages of simplicity and convenience in operation, rapidness in detection, multi-index joint detection and the like, and can provide powerful support for diagnosis of immune-related adverse reactions and other diseases.

Provided are methods for determining if an individual is likely to experience immune-related adverse events (irAEs) if treated for melanoma with a combination of immune checkpoint inhibitors that are an anti-Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) antibody and an anti-programmed death-ligand 1 (PD-1) antibody. The methods include determining differential gene signatures as between individuals who had melanoma and were treated with a combination of a CTLA-4 antibody and an PD-1 antibody but did not experience severe irAEs after the treatment, with the gene signature for an individual who has melanoma but was not treated with an immune checkpoint inhibitor.

Hybrid nuclease molecules and methods for treating an immune-related disease or disorder in a mammal, and a pharmaceutical composition for treating an immune-related disease in a mammal.